Levamisole as adjuvant to chemotherapy for canine lymphosarcoma.
Ninety-eight dogs with previously untreated lymphosarcoma were selected for study. All dogs were clinically staged and stratified on the basis of stage. All dogs were treated with combination chemotherapy (vincristine, L-asparaginase, cyclophosphamide, and methotrexate) and randomized to either a levamisole or placebo group. There was no significant difference in either remission time or survival time between the levamisole and placebo groups. Clinical stage, age, and body weight had no influence on remission or survival time. The most significant prognostic factor was sex: Female dogs had significantly enhanced remission time (p = 0.004) and survival time (p = less than 0.001).
D000818:Animals; D003131:Combined Modality Therapy; D004283:Dog Diseases / Q000188:drug therapy / Q000628:therapy*; D004285:Dogs; D005260:Female; D005500:Follow-Up Studies; D007167:Immunotherapy; D007978:Levamisole / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000628:therapy* / Q000662:veterinary*; D008297:Male
D007978:Levamisole